EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (AMEX:AIS) and the Population Council (an international, non-profit research organization) announced positive results from the Phase I trial for a novel contraceptive gel containing the progestin, Nestorone and the bio-identical estrogen, estradiol utilizing the Antares ATD™ (Advanced Transdermal Delivery) gel system.
